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Purpose: Multiple system atrophy (MSA) is an atypical parkinsonian syndrome and often difficult to discriminate
clinically from progressive supranuclear palsy (PSP) and Parkinson's disease (PD) in early stages. Although a
characteristic metabolic brain network has been reported for MSA, it is unknown whether this network can
provide a clinically useful biomarker in different centers. This study was aimed to identify and cross-validate
MSA-related brain network and assess its ability for differential diagnosis and clinical correlations in Chinese and
American patient cohorts.
Methods: We included 18F-FDG PET scans retrospectively from 128 clinically diagnosed parkinsonian patients
(34 MSA, 34 PSP and 60 PD) and 40 normal subjects in China and in the USA. Using PET images from 20
moderate-stage MSA patients of parkinsonian subtype and 20 normal subjects in both centers, we reproduced
MSA-related pattern (MSAPRP) of spatial covariance and estimated its reliability. MSAPRP scores were eval
uated in assessing differential diagnosis among moderate- and early-stage MSA, PSP or PD patients and clinical
correlations with disease severity. Regional metabolic differences were detected using statistical parameter
mapping analysis. MSA-related network and regional topographies of metabolic abnormality were cross-vali
dated between the Chinese and American cohorts.
Results: We generated a highly reliable MSAPRP characterized by decreased loading in inferior frontal cortex,
striatum and cerebellum, and increased loading in sensorimotor, parietal and occipital cortices. MSAPRP scores
discriminated between normal, MSA, PSP and PD subjects and correlated with standardized ratings of clinical
stages and motor symptoms in MSA. High similarities in MSAPRPs, network scores and corresponding maps of
metabolic abnormality were observed between two different cohorts.
Conclusion: We have demonstrated reproducible metabolic topographies associated with MSA at both network
and regional levels in two independent patient cohorts. Moreover, MSAPRP scores are sensitive for evaluating
disease discrimination and clinical correlates. This study supports differential diagnosis of MSA regardless of
different patient populations, PET scanners and imaging protocols.

1. Introduction
Multiple system atrophy (MSA) is a rare, fatal neurodegenerative
disorder characterized by symptoms of autonomic failure plus

parkinsonism, cerebellar ataxia, or both. It is still challenging to dis
tinguish MSA from idiopathic Parkinson’s disease (PD) and progressive
supranuclear palsy (PSP) with well-established clinical diagnostic cri
teria (Hughes et al., 2002; Obelieniene et al., 2018), especially in early
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Table 1
Demographic and clinical characteristics of normal controls and moderate-stage parkinsonian patients in the USA and China.
N
Combined moderate-stage cohort
Normal Control
20
MSA
20
PSP
20
PD
40
Moderate-stage American cohort
Normal Control
10
MSA
10
PSP
10
PD
20
Moderate-stage Chinese cohort
Normal Control
10
MSA
10
PSP
10
PD
20

Gender (M/F)

Age (years)

HY Scale

UPDRS (motor)

Duration (years)

7/13
10/10
12/8
26/14

62.3
61.7
65.5
61.0

±
±
±
±

8.8
7.4
8.4
5.2

N/A
3.9 ± 0.9*
3.9 ± 0.7*
2.7 ± 1.3

N/A
46.8 ± 14.5*
35.0 ± 12.4
31.3 ± 18.3

N/A
3.3 ± 2.4*
3.1 ± 1.7†
6.8 ± 4.6

3/7
3/7
5/5
14/6

64.3
63.7
68.1
60.1

±
±
±
±

7.6
8.7
5.8
5.4

N/A
4.6 ± 0.5‡
3.4 ± 0.9
3.1 ± 1.5

N/A
43.4 ± 17.1
26.2 ± 14.9‡
29.7 ± 18.8

N/A
3.5 ± 2.2
2.5 ± 1.2
9.3 ± 4.5§

4/6
7/3
7/3
12/8

60.2
59.7
62.8
61.9

±
±
±
±

9.9
5.7
10.0
5.1

N/A
3.6 ± 0.8
4.1 ± 0.6
2.5 ± 1.1

N/A
49.6 ± 11.9
39.5 ± 8.5
32.6 ± 18.3

N/A
3.2 ± 2.8
3.6 ± 2.0
4.8 ± 3.8

Data are given as mean ± standard deviation. MSA: multiple system atrophy; PSP: progressive supranuclear palsy;
PD: Parkinson’s disease; HY: Hoehn and Yahr; UPDRS: unified Parkinson’s disease rating scale. Modified from our previous study (Ge et al., 2018).
* P < 0.005 compared to the PD group in the combined cohort (post-hoc Bonferroni tests).
†
P < 0.001
‡
P < 0.05 compared to the corresponding group in the Chinese cohort (two-sample t tests).
§
P < 0.005

diagnosis (Rizzo et al., 2016). Given the great differences in patho
genesis, treatment response and prognosis among MSA, PSP and PD, the
accuracy of differential diagnosis and rigorous evaluation are very
important for both clinical and research applications.
Major clinical phenotypes of parkinsonism are neuropathologically
defined entities: MSA and PD belong to synucleinopathies with accu
mulation of α-synuclein aggregates in oligodendrocytes and neurons
respectively (Tong et al., 2010), while PSP and corticobasal syndrome
(CBS) are tauopathies with the core pathophysiology of tau fibrillar
aggregates (Boxer et al., 2017). Since parkinsonian disorders also in
volve the degeneration of dopaminergic neurons in the substantia nigra,
dopaminergic imaging can reveal abnormal nigrostriatal innervation
with several PET (Van Laere et al., 2010; Oh et al., 2012; Kaasinen
et al., 2019) and SPECT (Cummings et al., 2011; Tatsch and Poepperl,
2013; Kraemmer et al., 2014) radioligands. However, whether this
approach can differentiate atypical parkinsonism specifically from PD is
currently not yet confirmed (Stoessl et al., 2014; Ko et al., 2017).
Despite the clinical heterogeneity of disease manifestations, meta
bolic activity assessed with 18F-fluorodeoxyglucose (18F-FDG) PET in
conjunction with multivariate computing algorithms has revealed dis
ease-specific brain network patterns in parkinsonism (Ma et al., 2007;
Eckert et al., 2008; Teune et al., 2013; Matthews et al., 2018). It can
reliably differentiate between various parkinsonian syndromes even
during early stages (Spetsieris et al., 2009; Tang et al., 2010; Tripathi
et al., 2016) by measuring expression scores of multiple disease pat
terns prospectively in any new subjects. Of note, we have previously
cross-validated metabolic network patterns related with PD and PSP
respectively in Chinese populations against their American counterparts
(Wu et al., 2013; Ge et al., 2018). Although MSA-related pattern
(MSAPRP) had been defined independently in American and European
patients with predominantly parkinsonian subtype of MSA (MSA-P)
(Eckert et al., 2008; Teune et al., 2013), and was found to be similarly
expressed in American and Korea patients with both subtype of MSA-P
and subtype of MSA with cerebellar ataxia (MSA-C) (Poston et al., 2012;
Ko et al., 2017), this potential network marker for MSA has not yet been
vigorously cross-validated in multiple patient cohorts on different
scanners.
In this study we pursued these goals: (1) used multivariate brain
network analysis to identify MSAPRP in combined Chinese and
American patients with MSA-P and normal subjects; (2) evaluated
network scores in assessing differential diagnosis in moderate- and
early-stage patients with parkinsonism as well as clinical correlations

with disease severity; (3) conducted cross-validation to identify
MSAPRP in the American or Chinese cohort separately and measure its
activity in the other cohort; (4) localized brain regions with metabolic
abnormality in the same images and probed similarities/differences
across the two cohorts using univariate brain mapping analysis; (5)
examined the reproducibility of MSA-specific network and regional
metabolic characteristics across study populations, PET instruments
and analytic approaches.
2. Material and methods
2.1. Subjects
The vast majority of parkinsonian and normal (NL) subjects de
scribed in this article had been used in the previous report focusing
solely on the identification and validation of PSP-related metabolic
patterns (Ge et al., 2018). To identify and cross-validate MSAPRP be
tween different clinical centers, we retrospectivly selected two in
dependent cohorts of moderate-stage parkinsonian and NL subjects
from the USA and China in this study (n = 100). The American cohort
included 50 participants: 10 MSA-P, 10 PSP and 20 PD patients along
with 10 matched NL controls enrolled at North Shore University Hos
pital (NY, USA). To match the sample size the Chinese cohort was
comprised of the same numbers of subjects: 10 MSA-P, 10 PSP, 20 PD,
and 10 NL subjects recruited at the Department of Neurology of Hua
shan Hospital (Shanghai, China). All patients were rated clinically for
symptom severity by Hoehn and Yahr (HY) scale and the unified Par
kinson’s disease rating scale (UPDRS). All subject groups underwent
18
F-FDG PET at the respective study sites, and were highly similar in
their clinical and demographic information (Table 1). In the combined
American and Chinese cohort, age was matched across four subject
groups (F[3,96] = 1.8, P = 0.15; ANOVA). However, MSA/PSP pa
tients were more advanced in terms of clinical HY stages (P < 0.005;
post-hoc Bonferroni tests) and motor ratings (P < 0.005) but had
shorter disease duration (P < 0.005) than PD patients, suggesting
consistent motor symptoms among all patient groups. The American
cohort had more advanced clinical HY stages in MSA (P < 0.05, twosample t-test, two-tailed), lower motor ratings in PSP (P < 0.05) and
longer duration in PD patients (P < 0.005) compared to their Chinese
counterparts.
To further verify the value of MSAPRP in early differential diagnosis
we enrolled another independent Chinese cohort (n = 68) with early2
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Table 2
Demographic and clinical characteristics of normal controls and early-stage parkinsonian patients in China.

Early-stage Chinese Cohort
Normal Control
MSA
PSP
PD

N

Gender (M/F)

Age (years)

HY Scale

UPDRS (motor)

Duration (years)

20
14
14
20

12/8
8/6
9/5
14/6

56.9
52.1
65.6
50.9

N/A
2.6 ± 0.9§
3.2 ± 1.1§
1.5 ± 0.7

N/A
33.3 ± 12.8‡
29.6 ± 20.0
16.2 ± 7.9†

N/A
1.4 ± 0.5
1.5 ± 0.6
1.1 ± 0.5

±
±
±
±

11.5
7.2*
8.2§
11.3*

Data are given as mean ± standard deviation. MSA: multiple system atrophy; PSP: progressive supranuclear palsy;
PD: Parkinson’s disease; Hoehn and Yahr; UPDRS: unified Parkinson’s disease rating scale. Modified from our previous study (Ge et al., 2018).
* P < 0.005 compared to the PSP group (post-hoc Bonferroni tests).
†
P < 0.05
‡
P < 0.005 compared to the PD group (post-hoc Bonferroni tests).
§
P < 0.001

stage parkinsonian disorders: 14 MSA, 14 PSP and 20 PD patients along
with 20 matched NL controls (Table 2). These patients were initially
scanned with 18F-FDG PET at the Chinese site as clinically uncertain
cases and then followed up for several years until a clinical diagnosis
was made by their neurologists. MSA patients were presented with
parkinsonism and signs of autonomic symptoms within the first 2y from
disease onset; all MSA-P subtypes except one case diagnosed as MSA-C
after 2y of follow-up, given predominant cerebellar ataxia manifesting
progressively. Comparing this cohort to the combined cohort, MSA/PD
subjects were younger (P < 0.001) with PSP (P = 0.95) and NL
subjects (P = 0.11) closely matched in age; the patients had lower
motor ratings (MSA: P < 0.001; PSP: P = 0.39; PD: P < 0.0001; twosample t-tests, two-tailed) and shorter disease duration (P < 0.005).
The clinical diagnosis was unknown to the investigators involved in
imaging studies with the neurologists blinded to imaging outcomes
during clinical follow-up. Two senior specialists of movement disorders
followed all parkinsonian patients at each site for at least one year. A
probable diagnosis of MSA based on the consensus criteria (Gilman
et al., 2008) requires a sporadic, progressive adult-onset disorder in
cluding rigorously defined autonomic failure and poorly levodopa-re
sponsive parkinsonism or cerebellar ataxia. The non-motor symptoms
typically include lost smell, constipation, incontinence, orthostatic hy
potension and impotence, and comorbidities such as sleep behavior
disorder and depression (See data for all Chinese patients with MSA in
Supplementary Table 1). PSP and PD patients were screened based on
the NINDS-SPSP (Respondek et al., 2013) and the UK Brain Bank di
agnostic criteria (Hughes et al., 1992) respectively. Any parkinsonian
patients suspected of having other neurological diseases such as vas
cular parkinsonism had been ruled out by brain MRI scans during
routine clinical examination at both sites. All normal controls in this
study had no history of neurologic or psychiatric disorders without
prior exposure to neuroleptic agents or drug use. While the American
patients had moderate-stage parkinsonism as diagnosed clinically (Tang
et al., 2010), the vast majority of the Chinese patients at both early and
moderate stages had neurodegenerative parkinsonism as confirmed
retrospectively by differential reduction in striatal dopamine transpor
ters with PET (Insert Supplementary Fig. 1 here).
2.2.

clinical imaging protocol. All studies in patients and NL controls were
performed in a resting state in a quiet and dimly lit room.
Images were processed by Statistical Parametric Mapping (SPM5)
software (Wellcome Department of Imaging Neurosciences, Institute of
Neurology, London, UK) implemented in Matlab 7.4.0 (Mathworks Inc,
Sherborn, MA). All scans were spatially normalized into a standard
brain space and smoothened by a Gaussian filter of 10-mm FWHM over
a 3D space to increase the signal to noise ratio for statistical analysis.
2.3. Network analysis of metabolic activity
Metabolic brain network analysis was conducted using a voxelbased spatial covariance mapping algorithm termed SSM/PCA
(Spetsieris et al., 2009), implemented in ScanVp software freely avail
able online (http://www.feinsteinneuroscience.org at Center for Neu
roscience, the Feinstein Institutes for Medical Research, Manhasset,
NY). Briefly, by extracting covariance data in brain images after re
moving mean effects across voxels and subjects, group-wise PET data
(following natural log-transform) are reduced to a series of independent
covariance maps and corresponding subject scores. A disease-specific
metabolic pattern is defined by linearly combining a set of orthogonal
principal components (PCs) whose expression maximally discriminates
the patient and NL groups by logistic regression and whose topography
represents a spatially distributed network of functionally interrelated,
covarying brain regions. This covariance brain network depicts the
degree of regional covariation often described as loading on a voxel
basis. Here MSAPRP was first identified using 18F-FDG PET data from
moderate MSA-P and NL subjects in the combined American and Chi
nese cohort. The reliability of MSAPRP was estimated at each voxel
with a bootstrapping scheme (Habeck et al., 2008). Network scores of
MSAPRP were computed for all subjects (NL, MSA, PSP or PD) using a
voxel-based topographic profile rating algorithm (Ma et al., 2007; Peng
et al., 2014), by averaging the product of each image with the network
pattern over the brain.
To verify the consistency of MSAPRP between different centers we
next identified a separate MSAPRP using 18F-FDG PET scans of mod
erate MSA-P and NL subjects in the American or Chinese cohort. Intercohort cross-validation utilized two quantitative indicators of topo
graphic distribution and network expression. Regional loadings were
correlated between the two patterns among significant voxels (absolute
values ≥ 1.0) in the whole brain. Network scores of MSAPRP in the
American cohort were calculated for the subjects from China and
compared with those from the USA or vice versa. Network scores in
MSA and NL groups from the USA or China were also compared across
the two MSAPRPs. All network scores were Z-scored using subject
scores of the NL controls included in the identification of each MSAPRP.

18

F-FDG PET imaging and processing

All subjects were asked to fast for at least 6 h but had free access to
water, and antiparkinsonian medications in patients were withheld for
at least 12 h before PET imaging. The USA site used a GE Advance
tomograph (Milwaukee, WI). A PET transmission scan was first per
formed for attenuation correction with a 10-min emission scan acquired
in 3D mode between 35 and 45 min after intravenous bolus injection of
18
F-FDG (~185 MBq). The Chinese site used a Siemens Biograph 64
PET/CT (Munich, Germany). Following a short CT scan, a 10-min PET
scan was started 45-min post-injection. Only relative glucose metabolic
activity was measured as no arterial blood sampling was taken in this

2.4. Regional analysis of metabolic activity
Differences in regional metabolic activity between patients and
3
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controls were detected at each voxel according to the general linear
model in SPM software as we described (Ge et al., 2018). For the
American or Chinese cohort (together or separately), we performed a
two-sample t-test to characterize metabolic activity in moderate MSA
compared with controls. ANCOVA was used to model inter-subject
differences in global metabolic activity over the whole brain. We also
utilized a flexible factorial design to compare regional metabolic ac
tivity between the American and Chinese cohorts using SPM software
(Ge et al., 2018). The site and group were two main effects with global
values included as a covariate to remove the potential confound. The
regions with similar or different metabolic abnormality between the
American and Chinese MSA patients versus respective controls were
separately detected using conjunction or interaction analysis.
Significant brain regions were localized anatomically according to
our previous study (Ge et al., 2018). We set a height threshold at
P < 0.001 (uncorrected) over whole brain and searched for clusters
that also survived at family-wide error (FWE)-corrected P < 0.05. The
SPM maps for increased or decreased metabolic activity were overlaid
on a standard T1-weighted MRI brain template in stereotaxic space. To
quantify metabolic changes in specific regions post-hoc, we constructed
a 4-mm radius spherical volume of interest within the image space,
centered at the peak voxel of significant clusters in the SPM analysis.
Globally normalized metabolic values were then calculated in patients
and healthy controls with ScanVP software.

early-stage patients (ANOVA: F[3,64] = 23.3, P < 0.0001; Fig. 1C)
with elevation in MSA/PSP (P < 0.0001, post-hoc Bonferroni tests) but
not in PD (P = 1.0) versus NL groups. These scores in MSA and PSP
groups were similar (P = 0.85) although both were higher
(P < 0.0001) than in the PD group. Likewise, MSAPRP scores disclosed
increasing accuracy for discriminating MSA from PD/NL (AUC = 0.91)
or PSP from PD/NL (AUC = 0.93) in this early-stage patient cohort
(Supplementary Table 3). To realistically assess clinical correlates of
parkinsonism, patients were combined in early- and moderate-stage
cohorts. MSAPRP scores correlated with clinical HY stages (Spearman
test: r = 0.38, P = 0.04; Fig. 2A) and UPDRS motor ratings (Pearson
correlation: r = 0.44, P = 0.012; Fig. 2B) in the MSA group but not in
the PSP/PD groups (r ≤ 0.07, P ≥ 0.22). No correlations with disease
duration were present in any of patient groups.
3.2. Cross-validation of network patterns between the American and
Chinese cohorts
The separate analysis of moderate MSA-P and NL subjects in the
American or Chinese cohort probed the first 4 PCs with 53.9% or 54.4%
of subject × voxel variance. MSAPRP for each cohort was selected from
a linear combination of PC1 + PC2 + PC4 (28.3% VAF) or PC1 + PC4
(28.6% VAF) respectively. Both MSAPRPs revealed highly similar to
pographies (Fig. 3A/4A; c.f., Fig. 1A) which had strong voxel-based
correlations between regional loadings in the brain (r = 0.849,
P < 0.0001) and were also reliable according to bootstrapping with
1000 iterations (P < 0.01; Insert Supplementary Fig. 2B-C here).
Subject scores of both MSAPRPs for the four relevant groups are pro
vided in Table 4. ANOVA revealed effects of group across the American
derivation cohort and the Chinese validation cohort (F[3,36] = 72.9,
P < 0.0001; Fig. 3B) or vice versa (F[3,36] = 60.2, P < 0.0001;
Fig. 4B). Subject scores of either MSAPRP were elevated (P < 0.0001,
post-hoc Bonferroni tests) in MSA versus NL groups in both cohorts.
These scores in the two MSA groups were similar (P = 0.22) for the
American MSAPRP but differed (P = 0.0001) for the Chinese MSAPRP.
These scores correlated across both groups for the identification of
American MSAPRP and the validation of Chinese MSAPRP (Fig. 3C:
r = 0.867, P < 0.0001; MSA: r = 0.637, P < 0.05; controls:
r = 0.256, P = 0.475) or vice versa (Fig. 4C: r = 0.954, P < 0.0001;
MSA: r = 0.685, P < 0.05; controls: r = 0.421, P = 0.225).

2.5. Statistical analysis
Differences in MSAPRP scores or regional metabolic values over
multiple subject groups were assessed using one-way analysis of var
iance (ANOVA), with post-hoc contrasts examined by Bonferroni tests.
Discrimination of MSAPRP scores among parkinsonian patients at dif
ferent stages and NL subjects was determined by receiver operating
characteristic (ROC) analysis. Relationships between MSAPRP scores
and UPDRS motor ratings/disease duration, or between MSAPRP scores
with-subject across two MSAPRPs were evaluated by Pearson correla
tions with non-parametric Spearman correlation for clinical HY stages.
All analyses relied on SPSS software (SPSS Inc., Chicago, IL) and re
ported as significant at P < 0.05.
3. Results
3.1. MSA-related brain network pattern in the combined cohort

3.3. Differences in regional metabolic activity between MSA patients and
normal controls

Spatial covariance analysis of 18F-FDG PET scans in moderate MSAP and NL subjects from the USA and China evaluated the first 6 PCs
including 56.6% of subject × voxel variance. MSAPRP was selected
from a linear combination of PC1, PC2, PC3, PC4, and PC6 (24.9%
variance accounted for [VAF]) whose expression separated the groups
maximally in the logistic regression model. This pattern was char
acterized bilaterally by reduced loading in inferior frontal cortices,
striatum and posterior cerebellum, associated with increased loading in
precentral/postcentral gyrus, and parietal/occipital cortices (Fig. 1A)
and reliable according to bootstrapping with 1000 iterations
(P < 0.001; Insert Supplementary Fig. 2A here). Subject scores of
MSAPRP measured in this combined cohort of moderate parkinsonian
patients showed a group effect (ANOVA: F[3,96] = 133.1,
P < 0.0001; Fig. 1B) with elevation in MSA/PSP (P < 0.0001, posthoc Bonferroni tests) but not in PD (P = 1.0) compared to NL groups.
MSAPRP scores in PSP were also higher (P < 0.0001) than in PD but
lower (P < 0.0005) than in MSA. These scores exhibited increased
accuracy in discriminating MSA from PSP/PD/NL (area under the curve
[AUC] = 0.82 ~ 1.00) or PSP from PD/NL (AUC = 0.99 ~ 1.00) ac
cording to the ROC analysis (Supplementary Table 2). Furthermore,
MSAPRP scores did not differ between the two cohorts in NL, MSA, PSP
and PD groups (P ≥ 0.083, two-sample t-tests, two-tailed).
MSAPRP scores also showed a group effect in the Chinese cohort of

SPM analysis of 18F-FDG PET scans from the USA and China re
vealed bilaterally distributed metabolic abnormality associated with
moderate MSA-P compared to NL subjects (c.f., Insert Supplementary
Fig. 3 here; Insert Supplementary Tables 4-6 here). In the combined
data, relative metabolic activity decreased in middle/inferior frontal
gyri, striatum, claustrum and cerebellum, but increased in medial/
middle frontal, postcentral, inferior occiptial and superior/inferior
temporal gyri as well as precuneus and uncus (P < 0.001; most sur
vived at FWE-corrected P < 0.05). Regional metabolic differences
between moderate MSA and normal subjects were similar in the
American or Chinese cohort.
3.4. Similarities/differences in regional metabolic activity between the
American and Chinese cohorts
Conjunction analysis localized many bilaterally overlapping brain
regions of metabolic abnormality between the American and Chinese
cohorts. Comparing moderate MSA-P with NL subjects, metabolic ac
tivity decreased in inferior frontal gyrus, striatum, claustrum and cer
ebellum, but increased in superior frontal/cingulate, postcentral and
superior/middle temporal gyri, and hippocampus or parahippocampus
(Fig. 5A, Table 3; P < 0.001, with some regions survived at FWE4
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Fig. 1. MSAPRP identified by spatial covariance analysis of 18F-FDG PET scans from moderate-stage MSA patients and normal (NL) controls in the combined
American and Chinese cohort alongside MSAPRP expression for differential diagnosis. (A) Abnormal metabolic covariance topography in MSAPRP showing de
creased/negative (blue) and increased/positive (red) regional loadings coded by Z-scored values. (B) MSAPRP activity discriminated MSA from NL subjects in the
derivation sample (the two columns on the left) and from PSP or PD groups in the combined American and Chinese cohort at moderate stages. (C) MSAPRP activity
distinguished MSA from NL and PD subjects in the Chinese cohort at early stages. The error bars denote standard deviations. MSA: multiple system atrophy; PSP:
progressive supranuclear palsy; PD: Parkinson’s disease; MSAPRP: MSA parkinsonian-related pattern; L/R: left and right sides of the brain. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)

Fig. 2. MSAPRP expression for clinical correlations. MSAPRP activity correlated with clinical indicators of Hoehn and Yahr stages (A) and the Unified Parkinson’s
Disease Rating Scale (UPDRS) motor ratings (B) in the combined early- and moderate-stage MSA patients in China and moderate-stage MSA patients in the USA. MSA:
multiple system atrophy; MSAPRP: MSA parkinsonian-related pattern.

4. Discussion

corrected P < 0.05). Metabolic activity measured post-hoc in many
primary regions showed group effects (Table 4) and decreases in
striatum, claustrum, and cerebellum along with increases in superior
frontal/postcentral/middle temporal gyri in MSA versus NL subjects
across both cohorts (Fig. 5B-G; P < 0.05, post-hoc tests). Interaction
analysis revealed positive MSA-related metabolic changes in precentral
and middle occipital gyri, superior parietal lobule and cerebellum in the
American versus the Chinese cohort (Supplementary Fig. 4; Supple
mentary Table 7; P < 0.001, none survived at FWE-corrected
P < 0.05). The post-hoc analysis disclosed group effects (Table 4) with
increased metabolism in middle occipital gyrus and superior parietal
lobule in the American cohort but no changes in the Chinese cohort
comparing moderate MSA-P to NL subjects, with less decreased cere
bellar metabolism in the American cohort than in the Chinese cohort.

We examined the characteristics and consistency of abnormal me
tabolic topographies in two independent cohorts of moderate MSA-P
and normal subjects using multivariate and univariate analytic
methods. These techniques are geared toward identifying unique brain
networks with spatial covariance data or mapping differences in re
gional metabolic activity voxel-by-voxel using 18F-FDG PET images in
patients and normal controls (Ge et al., 2018; Habeck et al., 2008).
Network analysis generally recovers more disease-specific, widely dis
tributed brain regions that may not have direct biological correlates,
whereas regional analysis is closer to the diagnostic process based on
visual reading of clinical images. These two complementary approaches
focus on covariance brain network or regional metabolic differences
5
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Fig. 3. MSAPRP identified by spatial covariance analysis of 18F-FDG PET scans from moderate-stage MSA patients and normal (NL) controls in the American cohort.
(A) Abnormal metabolic covariance topography in MSAPRP showing decreased/negative (blue) and increased/positive (red) regional loadings coded by Z-scored
values. (B) MSAPRP activity discriminated moderate-stage MSA from NL groups in both the American and Chinese cohorts. The error bars denote standard de
viations. (C) Individual scores in the American cohort correlated highly across both NL subjects and MSA patients used for the identification of MSAPRP in the USA
and the validation of MSAPRP in China. MSA: multiple system atrophy; MSAPRP: MSA parkinsonian-related pattern; L/R: left and right sides of the brain. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

populations typically seen in clinical practice. We defined the covar
iance topography of MSAPRP in the combined American and Chinese
sample and characterized the diagnostic performance and clinical cor
relations with network scores computed prospectively in multiple pa
tient cohorts. Comparing the American and Chinese cohorts, MSAPRP

and provide quantitative means for delineating pathophysiological
changes in MSA at the systemic and local levels respectively.
This study included moderate-stage American and Chinese patient
cohorts and early-stage Chinese patient cohort with consistent demo
graphic and clinical characteristics, compatible with patient

Table 3
Overlapping brain regions with significant metabolic differences in moderate-stage MSA patients versus normal controls across the American and Chinese cohorts.
Structure

Brodmann Area (BA)

Hemisphere

MNI Coordinates*

Zmax

Cluster Size (mm3)

X

Y

Z

L
R
L
L
R
R
R
R

−56
60
−28
−14
18
16
34
2

18
16
−10
8
0
16
−8
−54

6
0
2
12
16
4
−2
−50

4.25
5.31
6.58
3.84
3.55
3.76
6.35
6.65

5000
6376
62,288
6312
1208

L
R
L
R
L
R
R
R
R
L

–22
22
−28
16
−14
20
50
56
36
−26

16
−16
−38
−40
−4
6
−54
–32
2
−10

68
70
54
66
52
52
6
−12
–32
−30

3.86
6.28
6.21
6.21
4.19
4.53
4.67
3.80
3.68
3.95

1120
253,496

†

Decreased Metabolism
Inferior Frontal Gyrus
Inferior Frontal Gyrus ‡
Lentiform Nucleus ‡
Caudate
Lentiform Nucleus
Caudate
Claustrum ‡
Cerebellar Tonsil ‡
Increased Metabolism †
Superior Frontal Gyrus
Superior Frontal Gyrus ‡
Postcentral Gyrus ‡
Postcentral Gyrus ‡
Cingulate Gyrus
Cingulate Gyrus
Superior Temporal Gyrus
Middle Temporal Gyrus
Middle Temporal Gyrus
Hippocampus/Parahippocampus

BA 45
BA 45

BA
BA
BA
BA
BA
BA
BA
BA
BA

6
6
3
4
24
24
39
21
21

* Montreal Neurological Institute (MNI) standard space.
†
Survived at uncorrected P < 0.001, extent threshold = 100 voxels (800 mm3).
‡
Survived at FWE P < 0.05. MSA: multiple system atrophy.
6

7720
73,552

1384
1008
4136
816
1000
4632

NeuroImage: Clinical 28 (2020) 102416

B. Shen, et al.

Table 4
Differences in brain network activity and regional metabolic values in moderate-stage MSA patients compared with normal controls across the American and Chinese
cohorts.

Network Analysis (SSM/PCA)
MSAPRP Activity (USA)
MSAPRP Activity (China)
Conjunction Analysis (SPM)
Decreased Metabolism
Inferior Frontal Gyrus (60 16 0)
Lentiform Nucleus (-28–10 2)
Caudate (-14 8 12)
Claustrum (34–8 −2)
Cerebellar Tonsil (2–54 −50)
Increased Metabolism
Superior Frontal Gyrus (–22 16 68)
Postcentral Gyrus (16–40 66)
Cingulate Gyrus (20 6 52)
Middle Temporal Gyrus (36 2–32)
Interaction Analysis (SPM)
Precentral Gyrus (-52–2 48)
Middle Occipital Gyrus (-26–94 12)
Cerebellar Tonsil (0–56 −44)

American Cohort
Normal Controls

MSASubjects

Chinese Cohort
Normal Controls

MSA Subjects

0.00 ± 1.00
0.00 ± 0.59

4.99 ± 1.22
3.91 ± 1.99†

0.00 ± 0.65
0.00 ± 1.00

4.57 ± 1.13
7.22 ± 1.65

72.9
60.2

46.3
81.5
66.3
91.3
83.0

±
±
±
±
±

5.2
4.8
5.7
3.4
5.5

41.9
70.2
56.9
78.6
73.7

±
±
±
±
±

4.7†
8.2
12.9
7.9
7.0†

41.9
85.2
69.7
88.0
86.5

±
±
±
±
±

4.5
4.1
13.7
5.5
5.1

34.2
71.5
53.8
75.3
62.5

±
±
±
±
±

4.7
8.2
10.7
5.4
5.3

10.9
12.5
4.5
17.3
34.7

65.0
80.1
79.4
57.4

±
±
±
±

4.0
4.3*
4.9
2.2*

69.7
87.9
79.8
61.2

±
±
±
±

3.8†
4.5†
2.8†
3.2†

66.6
84.0
81.7
52.0

±
±
±
±

8.0
3.3
2.7
4.4

75.9
96.0
87.7
55.0

±
±
±
±

5.1
6.2
6.2
4.4

7.7
21.1
7.7
11.3

96.3 ± 5.6
88.6 ± 7.2
64.8 ± 5.6

7.5
4.3
32.8

86.9 ± 2.8*
83.4 ± 3.6*
85.1 ± 5.9*

90.4 ± 6.0†
89.3 ± 4.5
76.3 ± 7.6†

94.0 ± 3.9
90.5 ± 2.5
90.6 ± 5.6

F value

‡

Subject scores and regional metabolic values are presented as mean ± standard deviation. MSAPRP activity values marked bold indicated subject scores in the
original derivation cohort with the other values computed prospectively in the validation cohort. MSA: multiple system atrophy; MSAPRP: MSA parkinsonian-related
pattern.
* P < 0.05 compared to the normal group in the Chinese cohort (post-hoc Bonferroni tests).
†
P < 0.05 compared to the MSA group in the Chinese cohort (post-hoc Bonferroni tests).
‡
P < 0.05 comparison among four independent groups in both cohorts (one-way ANOVA).

scores were in agreement for each of the moderate-stage parkinsonian
subgroups coinciding with their similar clinical features. In both earlyand moderate-stage patient cohorts, MSAPRP scores were elevated

differently in MSA/PSP but not in PD (greater in MSA but similar in
PSP/PD). These scores were independent of age but higher in woman
than men in PD despite minor gender mismatch in normal controls. Of

Fig. 4. MSAPRP identified by spatial covariance analysis of 18F-FDG PET scans from moderate-stage MSA patients and normal (NL) controls in the Chinese cohort. (A)
Abnormal metabolic covariance topography in MSAPRP showing decreased/negative (blue) and increased/positive (red) region loadings coded by Z-values. (B)
MSAPRP activity discriminated moderate-stage MSA from NL groups in both the Chinese and American cohorts. The error bars denote standard deviations. (C)
Individual scores in the Chinese cohort correlated highly across both NL subjects and MSA patients used for the identification of MSAPRP in China and the validation
of MSAPRP in the USA. MSA: multiple system atrophy; MSAPRP: MSA parkinsonian–related pattern; L/R: left and right sides of the brain. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
7

NeuroImage: Clinical 28 (2020) 102416

B. Shen, et al.

Fig. 5. Brain regions with similar metabolic abnormality in moderate-stage MSA patients compared to normal (NL) controls detected by conjunction analysis of 18FFDG PET scans with SPM across the American and Chinese cohorts. (A) Abnormal metabolic distribution of commonality (T-statistic maps) between the American
and Chinese MSA patients showing decreased blue) and decreased (red) relative metabolic activity represented by T-statistic values (P < 0.001). (B-G) Group
differences in relative metabolic values in select cortical and subcortical regions (4 mm-radius spheres) centered at the peak coordinates of significant clusters in the
prior SPM analysis on a voxel-by-voxel basis. The error bars denote standard deviations. MSA: multiple system atrophy; SPM: statistical parametric mapping; L/R: left
and right sides of the brain. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

note, MSAPRP scores provided high accuracy to distinguish MSA from
normal/PD but not from PSP subjects in the early- or moderate-stage
parkinsonian cohort (Fig. 1B-C; Supplementary Table 2-3). Moreover,
MSAPRP scores correlated positively with clinical HY stages and UPDRS

motor ratings (Fig. 2A-B) in MSA after combining early- and moderatestage patients. By contrast, no clinical association was seen in PSP or PD
suggesting that unique features captured in MSAPRP do not manifest
prominently in other forms of parkinsonism. The discrimination of MSA
8
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overall (R2 = 0.56 ± 0.17 [mean ± SD]; range = 0.39 ~ 0.73) using
the same common mask defined from the two patterns by thresholding
at |loading|≥1.0 (Supplementary Fig. 5A). The correlations were still
robust between the US and Chinese patterns (R2 = 0.67) with a mag
nitude of 0.48 ± 0.18 from the same set of bootstrap samples using the
common mask defined by thresholding at |loading|≥0.75 (Supple
mentary Fig. 5B). In addition, comparing the US pattern to its Chinese
counterpart, regional loading increased bilaterally in middle to superior
occipital/temporal and post-central regions as well as in left inferior
and precentral gyri at a lower threshold (Z-value = 2.0, P < 0.025,
one-tailed; see Supplementary Fig. 5C). Of interest these regions were
found to be located in less prominent territories in the original US and
Chinese patterns with absolute loading values smaller than 0.75. These
issues need to be further examined with large multi-center imaging
data. Subject scores of both MSAPRPs were comparable in MSA of the
American but not of the Chinese group. Nevertheless, these scores
correlated moderately in MSA patients but not in normal subjects for
whom MSAPRP was not supposed to be expressed. Moreover, we ob
served increased occipital metabolic activity in MSA in the US only with
greater cerebellar decline in China (Table 4). Like the heterogeneity of
MSA-related metabolic abnormality reported in prior studies these
discrepancies could be contributed to differences in patient samples,
imaging protocols and instrumentation (e.g., scanners, attenuation
correction methods and image reconstruction algorithms).
Population-dependent genetic heterogeneity may also impact on the
variation of metabolic network expression between the American and
Chinese cohorts (Schindlbeck and Eidelberg, 2018; Wu et al., 2013; Ge
et al., 2018). Although a genome-wide association study failed to reveal
any genetic correlates of MSA due to small samples and high rates of
misdiagnosis (Federoff et al., 2016), candidate pathogenic genes of
MSA such as SNCA and COQ2 were reported to differ among human
races in different geographic regions (Stamelou and Bhatia, 2016).
Nonetheless, this cross-validation study in two independent cohorts
proved that the disease-related metabolic characteristics were highly
reproducible in major cerebral regions of MSA on a whole-brain basis
(c.f., Fig. 1A/3A/4A), strongly supporting the notion that MSAPRP
expression is well-qualified to be a reliable imaging marker in clinical
diagnosis of MSA.
Although MSA cannot be accurately discriminated from PSP by
MSAPRP scores in the early-stage cohort they could be separated by
subject scores of PSP-related pattern as we reported (Ge et al., 2018). It
would be of interest to determine whether diagnosis between these two
atypical forms of parkinsonism could be enhanced by combining cor
responding subject scores and relative metabolic values in brain regions
defined by SPM analyses. This underscores the urgent need to improve
early differenential diagnosis by joint discrimination with multipledisease specific patterns (Tang et al., 2010; Tripathi et al., 2016) and
multi-tracer or dual-phase molecular imaging techniques (Südmeyer
et al., 2011; Jin et al., 2017). This study concludes the cross-validation
of three metabolic patterns across the Chinese and American parkin
sonian patient populations and paves the way for testing single-case
differential diagnosis prospectively with the use of multiple diseaserelated patterns in China.
Several limitations are present in this study: (1) The diagnostic ac
curacy of parkinsonism relied on clinical expertise at each center
without neuropathological confirmation. Nonetheless, the majority of
the patients enrolled in China had been confirmed by reduced striatal
dopaminergic function. (2) The sample sizes of MSA and normal sub
jects were relatively small at each site to keep with the MSAPRP ori
ginally established in the USA. These limited samples might be justifi
able given the more severe metabolic abnormality inherent in this
rapidly degenerative disease. This issue was mostly overcome by
combining all PET images from the two sites in a series of primary
analysis reported in this article. The fact that analogous metabolic
patterns were identified across two independent cohorts suggests that
the clinical diagnosis was reliable, and the sample sizes were adequate

from normal/PD subjects by MSAPRP scores and network correlation
with clinical disability in MSA are both in line with prior reports in
independent American and Korean patients (Poston et al., 2012; Ko
et al., 2017) demonstrating their specificity and utility for gauging the
symptomatology of MSA. Therefore, network scores of MSAPRP are
cross-validated for use as a quantitative marker of disease severity.
This work revealed MSA-related topographical similarities in mod
erate MSA-P patients at network and regional levels in both American
and Chinese cohorts when analyzed together or individually. The
MSAPRP topography is characterized bilaterally by negative/decreased
loading in inferior frontal gyrus, striatum and cerebellum with con
current positive/increased loading in sensorimotor, parietal and occi
pital cortices. This was generally consistent with the original study
depicting only negative/decreased striatal/cerebellar loading (Eckert
et al., 2008) and the subsequent report of both negative and positive
loadings in subcortical and cortical regions (Teune et al., 2013). Dif
ferences in the magnitudes of loading in MSAPRP suggested con
comitant regional metabolic abnormality underlyng the progression of
disease. The widespread cortical metabolic changes described in dif
ferent studies may be secondary to striatal and cerebellar dysfunction.
It is worth noting that cerebellar metabolic activity also decreased
markedly even in the analysis involving only MSA patients of parkin
sonian-type. We suspect that the rapid disynaptic pathway from the
cerebellar dentate nucleus to the striatum may provide a pathophy
siological basis for the simultaneous metabolic reduction in both cere
bellum and striatum in MSA-P (Chen et al., 2014; Caligiore et al., 2017).
The patterns of regional metabolic abnormality associated with
moderate MSA-P detected in this study mostly resembled topographies
of corresponding MSAPRPs in the combined or separate American and
Chinese cohorts (Insert Supplementary Fig. 3 here). Indeed, relative to
normal controls, relative metabolic activity in moderate MSA-P patients
decreased in inferior frontal gyrus, striatum and cerebellem, and in
creased in sensorimotor, parietal, temporal and occipital cortices as
reported before (Eckert et al., 2005; Teune et al., 2010). These regions
of reduced metabolic activity were also seen in patients with mixed
MSA subtypes (Lyoo et al., 2008) and lower putamen/claustrum me
tabolic activity also coincided with perfusion SPECT data (Van Laere
et al., 2004). Such relative metabolic decreases reflected largely brain
atrophy in these regions underlying this disorder (Nemmi et al., 2019;
Yang et al., 2019). Of note, some of the regions with increased meta
bolic values also extended to medial superior frontal gyrus and tha
lamus decribed previously (Eckert et al., 2005), which along with the
temporal gyrus were also evident in MSAPRP at a lower threshold
(reliabity P < 0.01). Such concordance can explain the elevated
MSAPRP activity in MSA (Fig. 1B/3B/4B) since subject scores reflect
similarity between individual metabolic images and the identified brain
network. Accordingly, the elevated MSAPRP activity in PSP reported
here and in Korean patients (Ko et al., 2017) also results from some
overlap in metabolic abnormality (e.g., frontal, temporal and occipital
cortices) between PSP and MSA (Eckert et al., 2005; Teune et al., 2010).
Thus, both network and regional analysis methods can effectively
identify MSA to a great extent given the inherent connection between
system and local metabolic characteristics.
Some differences in MSA-related metabolic characteristics across
two moderate-stage patient cohorts also existed in this study. Although
we saw very strong topographic correlation of MSAPRPs in the USA and
China (R2 = 0.72) its magnitude was smaller than those (0.84 ~ 0.86)
found previously for PDRP and PSPRP (Wu et al., 2013; Ge et al., 2018).
That accounted for ~ 72% of total variance but still left ~ 28% variance
unaccounted for. Of note, the MSAPRP from China has higher occipital
loading than that from the USA, which contributed to lower reliability
in such a relatively large region in the MSAPRP from the combined
American and Chinese sample (see Fig. 1A; Supplementary Fig. 2A). To
further explore residual differences in regional loading between the US
and Chinese patterns we analyzed randomly selected bootstrap samples
(n = 100 per pattern). This analysis revealed moderate correlations
9
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in this study. (3) Image normalization for the analysis were done with
SPM5 and its default brain perfusion PET template to be compatible
with our previous work (Wu et al., 2013; Ge et al., 2018). Before pur
suing differential diagnosis based on network scores there is a need to
migrate these disease-related patterns using newer versions of SPM and
standardized high-resolution brain templates to keep pace with the
progress of the field although no differences are anticipated between
SPM5 and SPM8 according to the network study in PD (Peng et al.,
2014). (4) This work focused on MSA-P but ignored the issue of MSA
clinical subtypes as only one patient in the early-stage cohort had pri
mary clinical features of MSA-C at follow-up but similar elevation in
MSAPRP activity as in MSA-P as reported (Poston et al., 2012; Ko et al.,
2017). More specific metabolic patterns may help better differentiate
patients with MSA-P and MSA-C or other potential MSA subtypes such
as pure autonomic failure in the future (Low et al., 2015). This is a topic
worth further investigations.

Wang: Conceptualization, Funding acquisition, Supervision, Project
administration. Yilong Ma: Conceptualization, Methodology, Funding
acquisition, Supervision, Writing - review & editing.
Declaration of Competing Interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ
ence the work reported in this paper.
Acknowledgments
The study at the Chinese site was funded jointly by the National Key
R&D Program (2016YFC1306504) from the Ministry of Science and
Technology of China, by the National Natural Science Foundation of
China (91949118, 81771372, 81701250, 81361120393, and
81671239), Shanghai Municipal Science and Technology Major Project
(No. 2017SHZDZX01, 2018SHZDZX03) and Science and Technology
Commission of Shanghai Municipality (19441903500, 17JC1401600).
The study at the American site was supported by the US-China
Biomedical Collaborative Research Program (R01 NS083490) from the
National Institutes of Health (NIH). The content is solely the responsi
bility of the authors and does not necessarily represent the official
views of the NIH. The sponsors played no roles in study design; in the
collection, analysis and interpretation of data; in the writing of the
report; and in the decision to submit the article for publication.

5. Conclusion
This study revealed similar topographies in spatial covariance brain
network and distribution of regional metabolic abnormality in subtype
of MSA-P by combining 18F-FDG PET images of moderate-stage patients
and normal subjects from American and Chinese medical centers. Crossvalidation between the two datasets confirmed highly reproducible
MSA-related metabolic brain networks and regional activity patterns of
cortical and subcortical abnormality across different patient popula
tions and imaging instrumentation/protocols. MSA-related brain net
work was reliable on a voxel basis and its expression in individual
subjects discriminated early to moderate MSA from normal controls or
PD and correlated with clinical variables of disease stage and severity.
Network score from 18F-FDG PET may serve as an objective biomarker
of MSA in patient care and clinical trials. Metabolic brain network in a
large cohort of pathologically-confirmed patients and normal subjects
from a single site or multiple centers can further establish the robust
ness of MSAPRP.
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